Lin MH, et al. Real-world brigatinib use in non-small cell lung cancer patients with prior use of crizotinib/other ALK therapies in the US. Abstract P2.16-09. WCLC 2019, 7-10 sept. Barcelona, Spanje.
Boosten maakt lagere dosering olaparib mogelijk
apr 2024 | Borstkanker, Gynaecologische oncologie, Uro-oncologie